Kezar Life Sciences, Inc.
- KZR
- NASDAQ
- Biotechnology
- Small Molecule Therapies
- Immuno-Oncology
$7.29
Quote May 11, 2026, 08:00 PM UTC
−1.09%over the last month
Max drawdown −2.2%From 1-month high −1.9%3 months +18.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Kezar Life Sciences
Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
55
Founded
2015
Market value
$53.9M
Quote May 11
Floor
$7.22
1.0% below price
Resistance
$7.34
0.7% above price
Price vs analyst targets
7 analysts
Lowest target
$5.00Highest target
$21.00
$5.00Highest target
$21.00
- Price $7.29
- Average target $11.00
- Analysts' target range
The price is close to the lowest analyst target. Analysts' average target sits about 51% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about KZRPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free